Int J Environ Res Public Health:银屑病能够增加突发感音神经性听力损失的风险

2020-12-31 AlexYang MedSci原创

银屑病是一种著名的免疫介导的疾病。其自身免疫病理生理学与免疫介导的系统性血管假说中关于突发感音神经性听力损失(SSNHL)的发病机制是一致的。

银屑病是一种著名的免疫介导的疾病。其自身免疫病理生理学与免疫介导的系统性血管假说中关于突发感音神经性听力损失(SSNHL)的发病机制是一致的。

最近,有研究人员调查了银屑病是否影响年龄、性别、收入和居住地区匹配的所有年龄组中SSNHL的发病率。研究人员从2002年至2013年收集了韩国健康保险审查和评估服务的全国患者样本,银屑病组包括12864名,对照组包括51456名。研究人员使用分层Cox比例危险模型分析了银屑病和SSNHL的简单和调整后(Charlson合并症指数)风险比(HR)。研究结果发现,银屑病组SSNHL的发生率显著高于对照组(0.5% vs. 0.4%,p=0.004)。银屑病增加了SSNHL的风险(调整后HR=1.44,95%CI=1.09-1.90,p=0.010)。在分层分析中,30-59岁组SSNHL的发生率显著高于其他组SSNHL(调整后HR=1.50,95%CI=1.06-2.12,p=0.023)。另外,SSNHL在男性银屑病患者中发生的频率明显更高(调整后HR = 1.70,95% CI = 1.17-2.49,p=0.006)。

最后,研究人员指出,银屑病增加了SSNHL的风险,而且SSNHL在30-59岁之间的患有银屑病的男性中更为普遍

原始出处:

Hyo Geun Choi , Bumjung Park , Seok Min Hong et al. Psoriasis Increases the Risk of Sudden Sensorineural Hearing Loss: A Longitudinal Follow Up Study Using a National Sample Cohort. Int J Environ Res Public Health. Dec 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1861418, encodeId=8519186141881, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 03 14:00:33 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035478, encodeId=35e820354e848, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Sat Sep 04 02:00:33 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306605, encodeId=a30e130660581, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524313, encodeId=289d1524313ec, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621881, encodeId=76cd16218819f, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=)]
    2021-12-03 shizhenshan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1861418, encodeId=8519186141881, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 03 14:00:33 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035478, encodeId=35e820354e848, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Sat Sep 04 02:00:33 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306605, encodeId=a30e130660581, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524313, encodeId=289d1524313ec, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621881, encodeId=76cd16218819f, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1861418, encodeId=8519186141881, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 03 14:00:33 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035478, encodeId=35e820354e848, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Sat Sep 04 02:00:33 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306605, encodeId=a30e130660581, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524313, encodeId=289d1524313ec, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621881, encodeId=76cd16218819f, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=)]
    2021-01-02 ysjykql
  4. [GetPortalCommentsPageByObjectIdResponse(id=1861418, encodeId=8519186141881, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 03 14:00:33 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035478, encodeId=35e820354e848, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Sat Sep 04 02:00:33 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306605, encodeId=a30e130660581, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524313, encodeId=289d1524313ec, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621881, encodeId=76cd16218819f, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=)]
    2021-01-02 july_979
  5. [GetPortalCommentsPageByObjectIdResponse(id=1861418, encodeId=8519186141881, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Dec 03 14:00:33 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035478, encodeId=35e820354e848, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Sat Sep 04 02:00:33 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306605, encodeId=a30e130660581, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524313, encodeId=289d1524313ec, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621881, encodeId=76cd16218819f, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Jan 02 06:00:33 CST 2021, time=2021-01-02, status=1, ipAttribution=)]

相关资讯

Clin Exp Hypertens:阻断IL-12和/或IL-23可改善主动脉血管炎

银屑病是一种T帮17型自身免疫性疾病,与心血管事件和死亡率的风险增加有关。乌斯替尼单抗是一种p40抗体,可阻断细胞因子IL-12和IL-23,是一种高效安全的银屑病治疗方法。我们进行了一项随机双盲安慰

第四届银屑病大会主题报告之精彩纷呈,聚焦银屑病前沿和发展

2020年10月23日上午,继第四届银屑病大会开幕式之后,国内外著名银屑病专家就银屑病最新的防诊治经验、银屑病防治概况及银屑病机制相关科研成果进行了大会主题报告。

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

百时美施贵宝(BMS)近日宣布,评估新型抗炎药deucravacitinib(BMS-986165)治疗银屑病的关键3期研究POETYK PSO-1达到了共同主要终点和多个关键次要终点。deucrav

头对头3期临床证实:抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

治疗第16周时,bimekizumab治疗后患者中有86.2%皮肤达到几乎清晰(PASI 90),而阿达木单抗组为47.2%(p <0.001)。

Acta Derm Venereol:口服混合益生菌菌株可有效且安全的治疗银屑病

这项为期12周的随机、双盲、安慰剂对照试验旨在确定益生菌混合物在减轻银屑病严重程度方面的有效性和安全性,研究结果已在线发表于Acta Derm Venereol。

Can J Cardiol:与环孢素或甲氨蝶呤治疗相比,抑制IL-17A可使血管和心肌功能得到更大的改善

白细胞介素(IL)-17A活性与银屑病有关。我们研究了IL-17A抑制对银屑病患者血管和左心室(LV)功能的影响,研究结果已在线发表于。